The neuronal ceroid-lipofuscinoses
- PMID: 12528813
- DOI: 10.1093/jnen/62.1.1
The neuronal ceroid-lipofuscinoses
Abstract
The neuronal ceroid-lipofuscinoses (NCLs) collectively constitute the most common group of neurodegenerative diseases in childhood and usually show an autosomal recessive mode of inheritance. Despite varying ages of onset and clinical course characterized in most instances by progressive mental and motor deterioration, blindness, epileptic seizures, and premature death, all forms of NCL show unifying histopathological features. There is accumulation of autofluorescent, periodic acid-Schiff-, and Sudan black B-positive granules that are resistant to lipid solvents in the cytoplasm of most nerve cells and. to a lesser degree, of many other cell types. The storage process is associated with progressive and selective neuronal loss and gliosis with secondary white matter lesions. The ultrastructure of the storage deposits varies between different forms of NCL and, along with the age of onset, has provided the basis for the traditional classification of NCLs. Recent molecular genetic findings have established that defects in at least 7 different genes underlie the various forms of NCL. The purpose of this paper is to provide an overview of the NCLs, review recent molecular genetic and biochemical findings, and discuss their impact on our views on the classification and pathogenesis of these devastating brain disorders.
Similar articles
-
The neuronal ceroid-lipofuscinoses: from past to present.Biochim Biophys Acta. 2006 Oct;1762(10):850-6. doi: 10.1016/j.bbadis.2006.06.010. Epub 2006 Jul 8. Biochim Biophys Acta. 2006. PMID: 16908122 Review.
-
The neuronal ceroid-lipofuscinoses: a historical introduction.Biochim Biophys Acta. 2013 Nov;1832(11):1795-800. doi: 10.1016/j.bbadis.2012.08.012. Epub 2012 Aug 29. Biochim Biophys Acta. 2013. PMID: 22959893
-
Molecular genetics of the NCLs -- status and perspectives.Biochim Biophys Acta. 2006 Oct;1762(10):857-64. doi: 10.1016/j.bbadis.2006.05.006. Epub 2006 May 27. Biochim Biophys Acta. 2006. PMID: 16828266 Review.
-
The neuronal ceroid lipofuscinoses: the same, but different?Biochem Soc Trans. 2010 Dec;38(6):1448-52. doi: 10.1042/BST0381448. Biochem Soc Trans. 2010. PMID: 21118105
-
Biochemical aspects of neuronal ceroid lipofuscinoses.Neurol Sci. 2000;21(3 Suppl):S21-5. doi: 10.1007/s100720070036. Neurol Sci. 2000. PMID: 11073224 Review.
Cited by
-
Reduction of neuroinflammation and seizures in a mouse model of CLN1 batten disease using the small molecule enzyme mimetic, N-Tert-butyl hydroxylamine.Mol Genet Metab. 2024 Sep-Oct;143(1-2):108537. doi: 10.1016/j.ymgme.2024.108537. Epub 2024 Jul 15. Mol Genet Metab. 2024. PMID: 39033629
-
Cln5 represents a new type of cysteine-based S-depalmitoylase linked to neurodegeneration.Sci Adv. 2022 Apr 15;8(15):eabj8633. doi: 10.1126/sciadv.abj8633. Epub 2022 Apr 15. Sci Adv. 2022. PMID: 35427157 Free PMC article.
-
Natural history of retinal degeneration in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses.Sci Rep. 2022 Mar 7;12(1):3670. doi: 10.1038/s41598-022-07612-7. Sci Rep. 2022. PMID: 35256654 Free PMC article.
-
A novel MFSD8 mutation in a Russian patient with neuronal ceroid lipofuscinosis type 7: a case report.BMC Med Genet. 2018 Aug 25;19(1):151. doi: 10.1186/s12881-018-0669-7. BMC Med Genet. 2018. PMID: 30144815 Free PMC article.
-
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.Sci Transl Med. 2020 Dec 2;12(572):eabb5413. doi: 10.1126/scitranslmed.abb5413. Sci Transl Med. 2020. PMID: 33268510 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
